Literature DB >> 4060575

Reversible inactivation and reactivation of vaccinia virus by manipulation of viral lipid composition.

M Oie.   

Abstract

The role of phospholipids in vaccinia virus was investigated by substituting viral lipids with specific phospholipids. Treatment of virus with sodium dodecyl sulfate, sodium deoxycholate, or Nonidet-P40 (NP-40) resulted in almost complete removal of viral lipid and led to inactivation of the virus. The inactivation induced by the former two was irreversible, but NP-40-treated virus was reactivated upon reassociation with phospholipids. Individual phospholipids, including phosphatidylserine (PS), phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, lysolecithin, sphingomyelin, and acyl bis(monoacylglycero)phosphate (ABMP), were tested for ability to reactivate NP-40-treated virus. Reactivation was induced only by PS. The infectivity of virus that had been treated with NP-40 and then with PS was unstable; the reactivated virus was inactivated within a short period. It was also very sensitive to trypsin. Treatment of NP-40-treated virus with mixtures of PS and ABMP yielded virus that was more resistant to spontaneous and trypsin-induced inactivation. Thus, PS appears to be an essential for infectivity and ABMP appears to play a supplementary role for maintenance of infectivity, perhaps by protecting against inactivating factors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4060575     DOI: 10.1016/0042-6822(85)90338-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry.

Authors:  Jason Mercer; Stephan Knébel; Florian I Schmidt; Josh Crouse; Christine Burkard; Ari Helenius
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

Review 2.  Poxvirus membrane biogenesis: rupture not disruption.

Authors:  Jacomine Krijnse Locker; Petr Chlanda; Timo Sachsenheimer; Britta Brügger
Journal:  Cell Microbiol       Date:  2012-12-16       Impact factor: 3.715

3.  Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein.

Authors:  Siti Khadijah Kasani; Huei-Yin Cheng; Kun-Hai Yeh; Shu-Jung Chang; Paul Wei-Che Hsu; Shu-Yun Tung; Chung-Tiang Liang; Wen Chang
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

4.  Coagulation initiated on herpesviruses.

Authors:  M R Sutherland; C M Raynor; H Leenknegt; J F Wright; E L Pryzdial
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

Review 5.  Membrane fusion during poxvirus entry.

Authors:  Bernard Moss
Journal:  Semin Cell Dev Biol       Date:  2016-07-14       Impact factor: 7.727

6.  Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entry.

Authors:  Jason P Laliberte; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-23       Impact factor: 11.205

7.  Lipid membranes in poxvirus replication.

Authors:  Jason P Laliberte; Bernard Moss
Journal:  Viruses       Date:  2010-04-06       Impact factor: 5.818

Review 8.  Poxvirus cell entry: how many proteins does it take?

Authors:  Bernard Moss
Journal:  Viruses       Date:  2012-04-27       Impact factor: 5.048

9.  Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.

Authors:  Mohammed Rafii-El-Idrissi Benhnia; Matthew Maybeno; David Blum; Rowena Aguilar-Sino; Michael Matho; Xiangzhi Meng; Steven Head; Philip L Felgner; Dirk M Zajonc; Lilia Koriazova; Shinichiro Kato; Dennis R Burton; Yan Xiang; James E Crowe; Bjoern Peters; Shane Crotty
Journal:  J Virol       Date:  2012-11-14       Impact factor: 6.549

Review 10.  Phosphatidylserine receptors: enhancers of enveloped virus entry and infection.

Authors:  Sven Moller-Tank; Wendy Maury
Journal:  Virology       Date:  2014-09-29       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.